Table of Contents Author Guidelines Submit a Manuscript
Canadian Journal of Gastroenterology and Hepatology
Volume 2016, Article ID 7321574, 8 pages
http://dx.doi.org/10.1155/2016/7321574
Research Article

Effectiveness of Second through Sixth Line Salvage Helicobacter pylori Treatment: Bismuth Quadruple Therapy is Almost Always a Reasonable Choice

Division of Gastroenterology, McGill University Health Center, McGill University, Montreal, QC, Canada H4A 3J1

Received 30 May 2015; Accepted 7 September 2015

Copyright © 2016 Tahir Shaikh and Carlo A. Fallone. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. R. Cave, “Transmission and epidemiology of Helicobacter pylori,” The American Journal of Medicine, vol. 100, pp. 12S–18S, 1996. View at Publisher · View at Google Scholar
  2. W. D. Chey and B. C. Y. Wong, “American College of Gastroenterology guideline on the management of Helicobacter pylori infection,” American Journal of Gastroenterology, vol. 102, no. 8, pp. 1808–1825, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. P. Malfertheiner, F. Megraud, C. A. O'Morain et al., “Management of Helicobacter pylori infection—the Maastricht IV/ Florence consensus report,” Gut, vol. 61, no. 5, pp. 646–664, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Qasim, S. Sebastian, O. Thornton et al., “Rifabutin- and furazolidone-based Helicobacter pylori eradication therapies after failure of standard first- and second-line eradication attempts in dyspepsia patients,” Alimentary Pharmacology and Therapeutics, vol. 21, no. 1, pp. 91–96, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. L. Gatta, A. Zullo, F. Perna et al., “A 10-day levofloxacin-based triple therapy in patients who have failed two eradication courses,” Alimentary Pharmacology and Therapeutics, vol. 22, no. 1, pp. 45–49, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. J. P. Gisbert, L. Gonzalez, and X. Calvett, “Systematic review and meta-analysis: proton pump inhibitor vs. ranitidine bismuth citrate plus two antibiotics in Helicobacter pylori eradication,” Helicobacter, vol. 10, no. 3, pp. 157–171, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. L. A. Fischbach, S. V. van Zanten, and J. Dickason, “Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies,” Alimentary Pharmacology and Therapeutics, vol. 20, no. 10, pp. 1071–1082, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. D. Y. Graham, F. Hammoud, H. M. T. El-Zimaity, J. G. Kim, M. S. Osato, and H. B. El-Serag, “Meta-analysis: proton pump inhibitor or H2-receptor antagonist for Helicobacter pylori eradication,” Alimentary Pharmacology and Therapeutics, vol. 17, no. 10, pp. 1229–1236, 2003. View at Publisher · View at Google Scholar · View at Scopus
  9. N. Vakil, “Primary and secondary treatment for Helicobacter pylori in the United States,” Reviews in Gastroenterological Disorders, vol. 5, no. 2, pp. 67–72, 2005. View at Google Scholar · View at Scopus
  10. B. J. McMahon, T. W. Hennessy, J. M. Bensler et al., “The relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for Helicobacter pylori infections,” Annals of Internal Medicine, vol. 139, no. 6, pp. 463–469, 2003. View at Publisher · View at Google Scholar · View at Scopus
  11. T. Rokkas, P. Sechopoulos, I. Robotis, G. Margantinis, and D. Pistiolas, “Cumulative H. pylori eradication rates in clinical practice by adopting first and second-line regimens proposed by the maastricht III consensus and a third-line empirical regimen,” The American Journal of Gastroenterology, vol. 104, no. 1, pp. 21–25, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. B. H. Lee, N. Kim, T. J. Hwang et al., “Bismuth-containing quadruple therapy as second-line treatment for helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate in Korea,” Helicobacter, vol. 15, no. 1, pp. 38–45, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. J. M. Lee, N. P. Breslin, D. K. Hyde, M. J. Buckley, and C. A. O'Morain, “Treatment options for Helicobacter pylori infection when proton pump inhibitor-based triple therapy fails in clinical practice,” Alimentary Pharmacology and Therapeutics, vol. 13, no. 4, pp. 489–496, 1999. View at Publisher · View at Google Scholar · View at Scopus
  14. D. Y. Graham and L. Fischbach, “Helicobacter pylori treatment in the era of increasing antibiotic resistance,” Gut, vol. 59, no. 8, pp. 1143–1153, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. C. Rodgers and S. V. van Zanten, “A meta-analysis of the success rate of Helicobacter pylori therapy in Canada,” Canadian Journal of Gastroenterology, vol. 21, no. 5, pp. 295–300, 2007. View at Google Scholar · View at Scopus
  16. A. L. Morse, K. J. Goodman, R. Munday et al., “A randomized controlled trial comparing sequential with triple therapy for Helicobacter pylori in an aboriginal community in the Canadian north,” Canadian Journal of Gastroenterology, vol. 27, no. 12, pp. 701–706, 2013. View at Google Scholar
  17. M. Pinchbeck and S. Veldhuyzen van Zanten, “Comparison of triple therapy, quadruple therapy and sequential therapy for the eradication of Helicobacter pylori infection,” Canadian Journal of Gastroenterology, vol. 26, supplement 1, article 138A, 2012. View at Google Scholar
  18. C. A. Fallone, A. N. Barkun, A. Szilagyi et al., “Prolonged treatment duration is required for successful Helicobacter pylori eradication with proton pump inhibitor triple therapy in Canada,” Canadian Journal of Gastroenterology, vol. 27, no. 7, pp. 397–402, 2013. View at Google Scholar · View at Scopus
  19. L. Gatta, N. Vakil, D. Vaira, and C. Scarpignato, “Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy,” The British Medical Journal, vol. 347, no. 7920, Article ID f4587, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. Y. Yuan, A. C. Ford, K. J. Khan et al., “Optimum duration of regimens for Helicobacter pylori eradication,” Cochrane Database of Systematic Reviews, no. 12, Article ID CD008337, 2013. View at Publisher · View at Google Scholar
  21. Y. I. Chen and C. A. Fallone, “A 14-day course of triple therapy is superior to a 10-day course for the eradication of Helicobacter pylori: a Canadian study conducted in a ‘real world’ setting,” Canadian Journal of Gastroenterology and Hepatology, vol. 29, no. 8, pp. e7–e10, 2015. View at Google Scholar
  22. C. A. Fallone, “Epidemiology of the antibiotic resistance of Helicobacter pylori in Canada,” Canadian Journal of Gastroenterology, vol. 14, no. 10, pp. 879–882, 2000. View at Google Scholar · View at Scopus
  23. R. H. Hunt, F. M. Smaill, C. A. Fallone, P. M. Sherman, S. J. V. van Zanten, and A. B. R. Thomson, “Implications of antibiotic resistance in the management of Helicobacter pylori infection: Canadian Helicobacter study group,” Canadian Journal of Gastroenterology, vol. 14, no. 10, pp. 862–868, 2000. View at Google Scholar · View at Scopus
  24. V. G. Loo, C. A. Fallone, E. De Souza, J. Lavallée, and A. N. Barkun, “In-vitro susceptibility of Helicobacter pylori to ampicillin, clarithromycin, metronidazole and omeprazole,” Journal of Antimicrobial Chemotherapy, vol. 40, no. 6, pp. 881–883, 1997. View at Publisher · View at Google Scholar · View at Scopus
  25. R. G. Lahaie and C. Gaudreau, “Helicobacter pylori antibiotic resistance: trends over time,” Canadian Journal of Gastroenterology, vol. 14, no. 10, pp. 895–899, 2000. View at Google Scholar · View at Scopus
  26. L. Best, G. Cooper-Lesins, D. Haldane et al., “Helicobacter pylori antibiotic resistance in Canadian populations,” Gastroenterology, vol. 126, Abstract S1293, p. A-189, 2004. View at Google Scholar
  27. L. M. Best, D. J. M. Haldane, G. S. Bezanson, and S. J. O. Veldhuyzen van Zanten, “Helicobacter pylori: primary susceptibility to clarithromycin in vitro in Nova Scotia,” Canadian Journal of Gastroenterology, vol. 11, no. 4, pp. 298–300, 1997. View at Google Scholar · View at Scopus
  28. S. V. van Zanten, S. Desai, L. Best et al., “Rescue therapy using a rifabutin-based regimen is effective for cure of Helicobacter pylori infection,” Canadian Journal of Gastroenterology, vol. 24, no. 5, pp. 303–306, 2010. View at Google Scholar · View at Scopus
  29. S. J. O. Veldhuyzen van Zanten, A. Farley, N. Marcon et al., “Bismuth-based triple therapy with bismuth subcitrate, metronidazole and tetracycline in the eradication of Helicobacter pylori: a randomized, placebo controlled, double-blind study,” Canadian Journal of Gastroenterology, vol. 14, no. 7, pp. 599–602, 2000. View at Google Scholar
  30. R. Lahaie, A. Farley, C. Dallaire et al., “Bismuth-based quadruple therapy with bismuth subcitrate, metronidazole, tetracycline and omeprazole in the eradication of Helicobacter pylori,” Canadian Journal of Gastroenterology, vol. 15, no. 9, pp. 581–585, 2001. View at Google Scholar · View at Scopus
  31. R. H. Hunt, C. A. Fallone, and A. B. R. Thomson, “Canadian Helicobacter Study Group. Canadian Helicobacter pylori consensus conference update: infections in adults,” Canadian Journal of Gastroenterology, vol. 13, no. 3, pp. 213–217, 1999. View at Google Scholar
  32. R. Hunt, C. Fallone, R. Hunt et al., “Canadian Helicobacter Study Group consensus conference: update on the management of Helicobacter pylori—an evidence-based evaluation of six topics relevant to clinical outcomes in patients evaluated for H pylori infection,” Canadian Journal of Gastroenterology, vol. 18, no. 9, pp. 547–554, 2004. View at Google Scholar · View at Scopus
  33. J. C. Delchier, P. Malfertheiner, and R. Thieroff-Ekerdt, “Use of a combination formulation of bismuth, metronidazole and tetracycline with omeprazole as a rescue therapy for eradication of Helicobacter pylori,” Alimentary Pharmacology and Therapeutics, vol. 40, no. 2, pp. 171–177, 2014. View at Publisher · View at Google Scholar · View at Scopus
  34. J. P. Gisbert, A. Perez-Aisa, L. Rodrigo et al., “Third-line rescue therapy with bismuth-containing quadruple regimen after failure of two treatments (with clarithromycin and levofloxacin) for H. pylori infection,” Digestive Diseases and Sciences, vol. 59, no. 2, pp. 383–389, 2014. View at Publisher · View at Google Scholar · View at Scopus
  35. J. P. Gisbert and X. Calvet, “Review article: rifabutin in the treatment of refractory Helicobacter pylori infection,” Alimentary Pharmacology and Therapeutics, vol. 35, no. 2, pp. 209–221, 2012. View at Publisher · View at Google Scholar · View at Scopus